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Aim: Thiazolidinones were prepared as building blocks for the replacement of carboxylic acids. Materials & 
Methods: Chemical syntheses of thiazolidinones were developed. In addition, the drug-likeness of the target 
compounds were evaluated in silico. Results: The prepared compounds included the novel structure 4; 5-(3-
Iodophenylmethylene)-2,4-thiazolidinedione. Conclusion: Exploration of the methods required to synthesise 
thiazolidinone building blocks was completed. This work allows future generation of bioisosteric analogues of drugs. 
Abstract: The presence of carboxylic acid moieties in drugs can present disadvantages such as low passive diffusion 
across biomembranes. A carboxylic acid may be substituted with a suitable bioisostere, for example a 
thiazolidinedione (TZD), in order to avoid such adverse effects. The in silico pharmacokinetic properties for TZD 
building blocks were evaluated. The novel precursor 4 was characterised by spectroscopy and microanalysis 
confirmed its molecular structure. Preliminary investigations of subsequent reduction of alkene conjugation and 
Suzuki-cross coupling reactions were attempted without success. Nonetheless, integrating 2-MeTHF presents a 
novel protocol for the lithium borohydride reduction of benzylidene TZDs. The methods presented have the 
potential to translate to the coupling of real drug motifs to TZD containing motifs.  
Keywords: bioisostere, thiazolidinone, carboxylic acid, building blocks. 
The carboxylic acid moiety is present in many endogenous substances like amino acids, triglycerides and 
prostanoids and plays a cardinal role in drug design. This functional group is part of a diverse family of drugs, 
exemplified by the fact that a significant number (>450) of marketed drugs are carboxylic acid containing molecules 
[1a]. Example drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), -lactam antibiotics [2], anticoagulants 
such as aspirin (which contains salicylic acid) and the eczema/dermatitis treatment betafucin (which contains fusidic 
acid) [3]. Nevertheless, despite the success of some carboxylic acid-containing drugs, the presence of this polar 
moiety can often be a disadvantage [4]. For instance, carboxylic acids can confer a limited ability to passively diffuse 
across lipid membranes such as those in the blood brain barrier and the intestine [5]. Moreover, metabolism of the 
carboxylic acid moiety (glucuronidation) can complicate pharmacotherapy, and its idiosyncratic toxicity may also 
present a problem [4]. A typical approach proposed by medicinal chemists, to circumnavigate such adverse effects, 
is the replacement of a carboxylic acid functional group with a suitable surrogate or bioisostere [1a, 4]. In general, 
bioisosterism is a concept defined by how a set of molecules exhibits physical and chemical similarities in relation 
to their biological interactions [6]. Judicious replacement of the carboxylic acid moiety is deemed successful if 
similarities exist between bioisosteres, coinciding with subtle modifications in order to improve levels of toxicity, 
stability, selectivity and/or absorption [4].  
 
As part of our eventual objective of assembling 96-well plates of proprietary building blocks featuring bioisosteres 
(see Figure 1), we intended to investigate the late-stage chemical attachment of building blocks to drug motifs for 
the production of proof-of-concept compounds. We envisaged use of an appropriate synthetic handle (aryl halide) 





Figure 1: Generation of a bioisostere building block ‘toolbox’ 
 
The construction of a versatile range of biaryls has been reported via the palladium-catalysed Suzuki cross coupling 
reaction using aryl halides [7, 8]. An example PPAR/FFAR1 dual agonist (1) belonging to this family with a 
thiazolidinedione (TZD) group at one terminus is depicted in Figure 2 [1b]. Moreover, compounds comprising these 
substructures constitute important building blocks in organic synthesis and medicinal chemistry [9]. We explored 
this approach to construct model adducts (Figure 4) as a first foray into reaching our objective of translating proof-
of concept methods to the coupling of real drug motifs to TZD-containing motifs (using molecular fragments bearing 
the appropriate functionality) in mind.  
       
Figure 2: Compound 1 (bearing a biphenyl motif)  
 
The aim of the methodologies proposed herein was to afford a reliable ‘toolbox’ necessary in establishing a 
catalogue of building blocks. In addition, the present work aimed to develop building blocks featuring a suitable 
bioisostere of the carboxylic acid moiety, thus allowing the pursuit of drug analogues. The chemical structures 
within this paper resemble the NSAID Felbinac (biphenylylacetic acid) and replacement of the carboxylic acid of 
Felbinac and related derivatives may be of interest to the wider community. As an aside, one of the phenyl rings of 
Felbinac has been replaced with a BN bioisostere using rhodium-catalysed arylation chemistry [10]. TZDs (also 
termed glitazones) have been shown to reduce insulin resistance [11], concurring with a rise in glucose disposal and 
reduced hepatic glucose production. TZDs are featured in the family of anti-diabetic drugs, used in the management 
of type 2 diabetes (e.g. pioglitazone and rosiglitazone; Figure 3). Members of the glitazone structural class stimulate 
the activation of the peroxisome proliferator activated receptor γ (PPARγ) [11]. Comparably, a diverse group of 
carboxylic acid-containing compounds (as drug-like candidates) have also been shown to stimulate the activation 
of PPARγ [12]. Furthermore, TZDs confer moderate acidity (pKa= 6-7) and relative lipophilicity [13]. This makes the 
TZD group prone to augmenting drug permeability and diffusion across biological membranes relative to 
corresponding carboxylic acids. Hence, by the bioisostere principle, TZD is a suitable surrogate. The utility of this 
 
 
strategy is already evident, for the TZD bioisostere has resulted in a broad range of important therapeutic agents 
[1]. 
  (a)  (b)  
 
Figure 3: PPARγ agonists pioglitazone (a) and rosiglitazone (b) 
 
We used the free in silico tool SwissADME [14] to predict ADME parameters and pharmacokinetic properties of the 
target molecules described herein. Accordingly, the in silico properties of target TZD building blocks, in conjunction 
with their corresponding carboxylic acids, were profiled in an effort to prioritise our synthetic efforts [15]. In this 
context, the physicochemical assessment of each building block dealt only with predicted permeability as barriers 
to absorption in relation to its suitability. Thus, as highlighted by Lipinski, a building block with a mass ≤450 Da, logP 
< 5, < 5 H-bond donors and < 10 H bond acceptors predicted that a drug is likely to be orally active. Moreover, Ertl 
established the desirable topological suitable polar surface area parameters (TPSA) for efficient permeability across 
membranes (blood brain barrier: 60-70 Å2; cell membranes > 140 Å2) [16].  
 
Our initial experiments centred on the preparation of halobenzylidene thiazolidinediones (BTZDs) [17a-e], bearing 
appropriate substitution on the aromatic ring. Access to novel structures is a constant goal of ours, however, we 
reasoned that synthesis of known compounds was also useful for method development. Several methods have 
reported on the synthesis of BTZDs; generally, these have followed a Knoevenagel or aldol condensation approach.  
Example literature findings disclose the use of piperidine and acetate in toluene [18], polyethylene glycol-300 [19], 
and sodium acetate in acetic acid [20]. Consequently, each of these methods suffer from several disadvantages 
such as drawn out work-up procedures, use of toxic solvents and/or requirement of special apparatus. To overcome 
these drawbacks, a solvent-free reaction procedure, using ethylenediamine and acetic acid, has been proposed [21, 
22]. Subsequently, the involvement of this Brönsted acid-base catalyst holds many advantages: the exclusion of 
toxic reagents; lower impact on the environment; and simplicity in process and handling. We describe the synthesis 
of BTZDs by the Knoevenagel condensation of aromatic aldehydes with TZD in the presence of ethylenediamine 
and acetic acid.  Relatively little information exists concerning the effectiveness of this approach regarding aryl 
halides. To help address these gaps, we explored novel reaction schemes involving 3-iodobenzaldehyde and 4-
bromobenzaldehyde with TZD (Figure 5). In addition, we investigated a literature aldol condensation scheme, for 
the purpose of cross-evaluating reaction schemes [31].  
 
Experimental 
Reagents & Equipment  
Reagents, solvents and catalysts were purchased from Sigma Aldrich (Gillingham, Dorset, UK) and were used 
without further purification. The hotplate magnetic stirrer used was supplied by Camlab (MS-H280-Pro). TLC 
analyses were performed using aluminium backed silica gel coated plates (60F254) and developed using UVGL-58 
Handheld UV Lamp (254-365nm). Flash chromatography was performed using Davisil® chromatography grade silica 
(pore size 60 angstrom, particle size 35-70 micron). Melting points were determined on a Gallenkamp (electronic) 
apparatus. IR spectra were recorded on a Nicolet iS5 FTIR spectrometer, with the Thermo ScientificTM iD7 ATR-
diamond accessory included.    NMR spectra were recorded on an Oxford NMR ADVANCE II instrument operating 
at 400 MHz for 1H and 13C NMR, and were performed in DMSO-d6 solutions (signals are recorded as /ppm). Mass 






The reaction schemes shown in Figure 4 illustrate our efforts to prepare 4-8 and 9a-b. 
 
(i) Synthesis of 4-5 using PhMe, NaOAc, 180oC, molecular sieves or ethylenediamine, AcOH, 80oC (16-42% yield; see Table 2). (ii) Attempted conversion of 4 (to 
6) using LiBH4, 2-MeTHF, pyridine, 110oC gave no reaction. (iii): Attempted conversion of 4 (to 7)and 5 (to 8) using either 4-Methoxyphenylboronic acid, K2CO3, 
Pd/C, H2O, RT or 4-Methoxyphenylboronic acid, K2CO3 and either Pd/C, H2O, RT or Pd(OAc)2, PhMe, 90oC gave no reaction. (iv) Future reactions. 
Figure 4: Summary of synthetic attempts to access TZD building blocks: (i) condensation reaction; (ii) reduction; (iii) cross coupling reaction.  
 
Results & Discussion 
Determination of predicted physiochemical/ADME properties  
 
The SwissADME application [14] enabled the swift identification of appropriate drug-like building blocks. Early 
evaluation of the ADME parameters (Adsorption, Distribution, Metabolism and Excretion) may reduce the 
proportion of unsuccessful molecules resulting from pharmacokinetics-related issues. 
 
The results from a study of conceivable building blocks are depicted in Table 1. As demonstrated, a TZD surrogate 
can lead to considerable variations in physiochemical properties in relation to the carboxylic acid moiety. The 
criteria set by Lipinski and Ertl, aided our selection of molecules with drug-like character. As shown in Table 1, the 
TZD containing building blocks exhibit greater LogPo/w values than their carboxylic acid isosteres (compare entries 
ii and iv with i and iii). Correspondingly, the increased lipophilicity of a molecule will increase its value of LogPo/w. 
These properties imply that the more polar carboxylic acid moiety can display relatively high-water solubility, an 
important characteristic for a drug-like candidate. Nonetheless, these aspects may also be linked to a compound’s 
limitations [23]. A key possible deficit of the carboxylic acid moiety, is attributed to its short half-life (if metabolic 
turnover is relatively rapid). The limitation of a short half-life may be attributed to low LogPo/w by the associated 
promotion of rapid metabolic conversion (glucuronidation). This may induce serious adverse side effects, caused 
by the covalent modifications of proteins, succeeding from the metabolites (acyl glucuronides) [23].  
However, an elevated value of the LogPo/w value will decrease the aqueous solubility of the compound (TZDs). 
Hansch and Leo proposed that highly lipophilic molecules will be partitioned and retained at the lipid interior of the 
cell membrane [24]. Hence, this may lead to the poorer absorption of drug candidates. TPSA is described as the 
sum of molecular surface areas arising from polar nitrogen and oxygen atoms together with their attached 
hydrogen atoms [16]. Such forces are involved as a molecule approaches the polar surface of a cell membrane. As 
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ii and iv of Table 1), it is desirable that each building block be only minimally functionalised. By this criteria, entries 
i and iii (compounds 9a-b, Table 1) present biaryl scaffolds that are deemed unsuitable for possible BBB penetration. 
Nonetheless, permeability of the cell membrane is still predicted to be viable as the TPSA values of TZDs depicted 
in entries i and iii (Table 1) do not exceed 140 Å2 [25]. Consequently, binding to the PPARγ receptor (found primarily 
in adipose tissue) could be possible, enabling the TZD-containing compounds to exert a glucose lowering effect [26]. 
The scaffold of the building block must not disrupt the core physicochemical properties of the TZD surrogate. A 
short aliphatic spacer was deemed desirable in order to minimise the possible aqueous solubility deficiency caused 
by the conjugation of the biaryl scaffold (compare 9a-b with compounds 7-8).  
 
Table 1: Summary of results gained using SwissADME for various properties of TZD- and carboxylic acid-containing biaryl building blocks. 
The relative molecular mass (RMM, g.mol-1), topological polar surface area (TPSA, Å2), LogPo/w, and permeability across the blood brain barrier 
(BBB) are highlighted.  
Entry Building block RMM TPSA Consensus LogPo/wa BBB permeant Lipinski 
i 9a (see Figure 4) 313 80.7 2.97 No 0 violations 
ii 
 
258 49.7 2.87 Yes 0 violations 
iii 9b (see Figure 4)  313 80.7 2.97 No 0 violations 
iv 
 
258 49.7 2.87 Yes 0 violations 
 
aAverage of all five LogPo/w predictions: ILOGP, XLOGP3, WLOGP, MLOGP, SILICOS-IT. 
 
Establishing the building blocks 
 
The versatility of Suzuki cross coupling reactions between aryl boronic acids and aryl halides, in the 
presence of a palladium catalyst, has been well demonstrated [7, 27-29]. Comparably, such 
organoboron reagents exhibit greater functional group compatibility than their organo-metal 
counterparts for instance, organozinc and Grignard reagents [30]. Monosubstituted phenylboronic 
acids are commonly inexpensive and their innocuous nature serves to provide benefits such as low 
toxicity and high stability. Moreover, the mode of reaction can be conducted in an aqueous media, 
which provides economic and environmental advantages [28]. Ortho- and para- substitution of aryls 
have been thoroughly examined, however meta-selective C–H functionalization has been less 
explored [29]. We reasoned that substitution at the meta position could be significant in expanding 
the catalogue of TZD building blocks and subsequent drug candidates (see 7, for example, in Figure 4).   
 
Furthermore, reduction of the alkene present in 4-5 would give rise to 9a-b (Figure 4). Giles et al. 
proposed a suitable reaction scheme for this process that incorporated use of lithium borohydride in 
THF/pyridine. Their procedure afforded a high yield with relatively short reaction time, demonstrating 
10a (R
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the high selectivity of the reagent as a BTZD reducing agent [31]. Critically, the procedure proposed by 
Giles was deemed to be not in keeping with our ‘green chemistry’ philosophy. We envisaged that the 
commercially available solvent 2-methylTHF, afforded from renewable resources, presents an 
appropriate modification to this reduction process [32].  
 
The results from our efforts to prepare halobenzyl thiazolidinediones (in 16—42% yield) are 
summarised in Table 2. From the corresponding halo-benzaldehyde (2) and TZD (3), 4 was prepared 
using a modified form of the reported method by Giles et al. [31]. The condensation process was 
carried out using sodium acetate in refluxing toluene but, in our hands, no identifiable products were 
isolated using this reaction temperature. In an endeavour to assist the aldol condensation, acetic acid 
was incorporated into the reaction mixture at 180°C [30]. Molecular sieves were included to remove 
any subsequent water production. In accordance with Le Chatelier’s Principle, this protocol should 
increase the rate of the forward reaction process, yielding product 4. This procedure presented a 
conceivable one-pot means of procuring precursors of our desired building blocks. An example 1H 
NMR diagnostic observation was the singlet at 7.73ppm illustrating the formation of the carbon-
carbon double bond present in compound 4.  
 
Table 2: Preparation of halobenzyl thiazolidinediones  
 
 
Entry X1 X2 Time for condensation (h) 
Yield of 4-5 
(%) 
a I H 6 16a 
b I H 1.5 29 
c H Br 2.0 N.R. 
d H Br 64 42 
e I H 64 28 
a: PhMe, NaOAc, 180oC, molecular sieves; b-e: Ethylenediamine, AcOH, 80oC (N.R.: No reaction. aYield of crude 4). 
  
In contrast to the aldol condensation-mediated production of 4 we found other 
Knoevenagel condensations proceeded smoothly to produce 4-5. The quantity of catalyst and reaction 
time had important effects on the reaction. In accordance with Zhang and Zhou [22], 80°C was chosen 
as the reaction temperature. Ethylenediamine and acetic acid were employed for the synthesis of 4 
and, after 1.5 hours, the product precipitated out of solution (entry 2, Table 2).  
Next, we attempted to transpose these reaction conditions to the synthesis of 5. However, the initial 
practice involving para-bromo benzaldehyde gave rise to various complications. In contrast to 4, TLC 
analysis identified the formation of two products and attempted recrystallisation (using ethyl acetate 
and hexane) or flash chromatography did not aid purification. As such, the reaction procedure used 
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for the synthesis of compound 5 could not be emulated for the formation of 4 (suggesting the starting 
aldehydes react differently). We modified the procedure (to avoid tedious extraction procedure) by 
prolonging the reaction time. Moreover, the concentration of both ethylenediamine was increased 
and the quantity of acetic acid reduced (keeping the amount of 4-bromobenzaldehyde constant at 
3.21mmol). Thus, a greater yield of pure 5, with an observed melting point range of 242-244°C (Found: 
252-253°C; [31]) was obtained. This effective methodology was emulated in order to yield the novel 
iodide 4. Despite the prolonged reaction time, partnered with the altered concentrations of 
ethylenediamine and acetic acid, there was no increase in yield. Spectroscopic and microanalysis 
confirmed the formation of the novel iodo-BTZD 4.  
The methodology used for the attempted regioselective reduction of 4 to 6 was adapted from Giles et 
al [31]; the inclusion of pyridine was reported to modify the reactivity of the LiBH4, to selectively 
reduce the alkene function. Accordingly, 4 was dissolved in dry 2-MeTHF and the incorporation of this 
solvent, as a substitute for THF, is well founded. 2-MeTHF presents a more stable solvent than THF 
during lithiation reactions [32] and, as such, 2-MeTHF offers a sustainable/eco-friendly alternative to 
THF. Thus, the reaction was ceased, after refluxing for 6 hrs, as per the literature [33] but 1H NMR 
analysis after work-up revealed that the starting material was returned (Figure 4). We are currently 
investigating the synthesis of 9a-b from derivatives 7-8 (Figure 4). 
We intended to investigate a late stage functionalisation of aryl halides using Suzuki-type conditions 
in the presence of TZD sulfur atoms. A similar strategy involving early-stage Suzuki coupling between 
a sulfur-containing TZD unit and meta-bromide is precedented [34]. Our attempted synthesis of 7-8 
was adapted from Sakurai’s methodology for the room temperature generation of BTZDs [28]. 
Palladium on carbon offers an efficient, ligand free and heterogenous catalysed protocol for the 
coupling of 4-5 and boronic acids. The premise of incorporating Pd/C is founded on its stability in open 
air/water and to base, often not requiring solvent degassing or an inert atmosphere.  After 4 and 5 
were reacted with 4-methoxyboronic acid in the presence of K2CO3 and Pd/C, at room temperature, 
no 1H NMR signals consistent with the desired products were present after analysis of the crude 
mixtures and starting material was returned in each case (see Table 3). Also, attempted Suzuki 
coupling between 5 and 4-methoxyphenylboronic acid in the presence of Pd(OAc)2 and hot toluene 
did not yield the desired product, 8. Further studies here could include the use of prolonged heating 
and the incorporation of varying solvents, to optimise the Suzuki cross-coupling scheme [1]. Earlier 
incorporation of the aryl group prior to condensation with TZD may also be worth exploration in case 
the sulfur affects the catalyst [35]. However, evidence of Suzuki couplings in TZD-containing systems 
has been reported [34]. 
Table 3: Attempted palladium cross-coupling reactions 
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Time for coupling (h) 
Yield of 7 or 
8 (%) 
a 4 24 N.R. 
b 5 65-66 N.R. 
 
a: 4-Methoxyphenylboronic acid, K2CO3, Pd/C, H2O, RT. b: 4-Methoxyphenylboronic acid, K2CO3 and either Pd/C, H2O, RT or Pd(OAc)2, PhMe, 
90oC.  N.R.: No reaction. 
Conclusions 
In summary, our building block in silico studies suggested that the TZD replacement for a carboxylic 
acid presented no pharmacokinetic violations following the guidelines set by Lipinski. However, blood-
brain barrier penetration may not viable for compounds 9a-b; Ertl [16] describes that permeability is 
permitted when TPSA is lower than 80 Å2. Nonetheless, as the abundance of PPARγ is stored primarily 
within adipose tissue, cell membrane permeability would be required for treatments of metabolic 
disease and, hence, the building blocks 7-8 adhere to the enclosed guidelines (TPSA < 140 Å2). Our 
reaction schemes were aimed at presenting a facile and environmentally benign means of obtaining 
each building block. It has been shown, that ethylenediamine and acetic acid can be used as a catalytic 
alternative to the aldol condensation of sodium acetate and acetic acid (4), for the preparation of 
BTZDs. Minimal purification steps, recyclable amine catalyst and higher yields are the core benefits 
presented by this protocol and the formation of the novel compound 4 was confirmed. Moreover, the 
para substituted alternative was also obtained (5). However, the optimum amine concentration 
remains to be established and, in addition, further investigation could ascertain the ideal reaction 
conditions for each benzaldehyde. A novel solvent application of 2-MeTHF was explored, during the 
lithiation reduction attempt of a BTZD. Despite the limitations presented in the enclosed experimental 
(return of starting material), our studies around the synthetic utility of 2-MeTHF are continuing in 
combination with lithium borohydride. It has been shown to be an effective solvent for low 
temperature lithiation reactions [32].  
Both heterogenous and homogenous palladium catalysed reactions were explored, for the 
attachment of a phenyl ring onto a TZD scaffold via a ‘synthetic handle’. Further studies in this area 
will be reported on in due course. Optimisation of catalyst loading in conjunction with a less viscous 
solvent (such as DMAc), at a higher temperature, may yield the necessary rate of diffusion for a 
successful catalytic process.        
Future perspective 
The methods presented have the potential to translate to the coupling of real drug motifs to TZD 
containing motifs. In other words, potential (larger) drug molecules could be assembled using building 
blocks such as 4. Further refinement of chemical methodology is in progress in our laboratory for the 
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application to real carboxylic acid-containing drug candidates and storage of solutions of building 
blocks in a 96-well plate library format. The construction of biaryls, as illustrated in Figure 4, generated 
examples of model building blocks. Although the disclosed methodologies evaluate the synthesis of 
biaryl building blocks, the reaction schemes illustrated are not limited to this role. In future, more 
suitable drug like candidates could be viably established and we plan to explore how their 
biological/ADME profiles compare to reference drugs such as pioglitazone. In terms of in silico 
perspectives, it seems reasonable that such molecules could stabilize the ligand binding domain of 
PPAR given that the binding modes of TZDs are well conserved [36]. 
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• Chemical routes for the synthesis of thiazolidinones were investigated. 
• The drug-likeness of the target compounds were evaluated in silico. 
Results & discussion 
• A set of TZD building blocks, including novel iodide 4, were prepared with the intention of replacing 
carboxylic acid motifs. 
Conclusion 
• Exploration of the synthetic methods studied will allow for future generation of bioisosteric 
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